Clinical Trials Logo

Osteogenesis Imperfecta Type III clinical trials

View clinical trials related to Osteogenesis Imperfecta Type III.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05559801 Not yet recruiting - Clinical trials for Osteogenesis Imperfecta

Mesenchymal Cell Therapy in Osteogenesis Imperfecta (OI)

Start date: September 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2 study to determine the safety and efficacy of allogeneic (third party), bone-marrow derived mesenchymal stromal cells (MSCs) for the treatment of Osteogenesis Imperfecta (OI) Type 3. It will evaluate this by looking at whether there are treatment related infusion reactions, and assessing linear growth rates and bone health, both of which are impaired in patients ages 3-10 with Osteogenesis Imperfecta Type 3. This is a single-site non-randomized clinical trial, that will take place at Children's Healthcare of Atlanta (CHOA) at Egleston and Emory Children's Center.